Crossmark

Is the Treatment Worse than the Disease?: Key Stakeholders’ Views about the Use of Psychiatric Electroceutical Interventions for Treatment-Resistant Depression

Crossref DOI link: https://doi.org/10.1007/s12152-024-09573-2

Published Online: 2024-10-16

Published Print: 2025-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Cabrera, Laura Y. https://orcid.org/0000-0002-6220-7096
Bluhm, Robyn https://orcid.org/0000-0002-4187-0569
McCright, Aaron M. https://orcid.org/0000-0001-6251-5251
Achtyes, Eric D. https://orcid.org/0000-0001-8939-1535
Funding

Funding for this research was provided by:

National Institute of Mental Health (RF1MH11780)
License Information

Text and Data Mining valid from 2024-10-16

Version of Record valid from 2024-10-16
More Information

Article History

Received: 10 April 2024

Accepted: 11 October 2024

First Online: 16 October 2024

Declarations

:

: LC, RB, and AM have no conflicts of interest to declare. EA has received research support from the following entities in the preceding 12 months: Alkermes, Boehringer-Ingelheim, Janssen, Karuna, Neurocrine Biosciences, Teva, and the Vanguard Research Group. EA also has served on advisory boards or consulted with Alkermes, Boehringer-Ingelheim, Clinical Care Options, CMEology, CME Outfitters, and VML Health.

Document is current

Any future updates will be listed below